Dose-dependent neutralizing-antibody responses to vaccinia

J Infect Dis. 2004 Feb 1;189(3):493-7. doi: 10.1086/380906. Epub 2004 Jan 23.

Abstract

To evaluate the humoral immune responses to smallpox-vaccine stocks currently available in the United States (Dryvax; Wyeth) and to generate data for comparison of responses to newly produced lots of smallpox vaccine, we evaluated dose-response effects, using undiluted and diluted smallpox vaccine. At 28 and 56 days after vaccination, serum samples were obtained from vaccinated subjects (N=674) who had participated in a randomized, single-blinded trial of an undiluted or a 1 : 5 or 1 : 10 dilution of smallpox vaccine and who subsequently were tested for plaque-reduction neutralizing-antibody titer. All subjects who developed a vesicle after vaccination also developed neutralizing antibodies by day 28. Subjects given either a 1 : 5 or 1 : 10 dilution of vaccinia had significantly higher neutralizing-antibody titers than did subjects given undiluted vaccine. Larger lesion size and fever after vaccination were associated with significantly higher neutralizing-antibody titers after vaccination.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Viral / blood
  • Blister / pathology
  • Dose-Response Relationship, Immunologic
  • Female
  • Fever / pathology
  • Humans
  • Male
  • Neutralization Tests
  • Single-Blind Method
  • Smallpox Vaccine / administration & dosage*
  • Smallpox Vaccine / adverse effects
  • Smallpox Vaccine / immunology
  • United States
  • Vaccination*
  • Vaccinia / blood
  • Vaccinia / immunology*
  • Vaccinia / pathology
  • Viral Plaque Assay

Substances

  • Antibodies, Viral
  • Smallpox Vaccine